{"id":"NCT00635089","sponsor":"Ception Therapeutics","briefTitle":"Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis","officialTitle":"An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2008-03-13","resultsPosted":"2017-03-23","lastUpdate":"2017-03-23"},"enrollment":190,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis"],"interventions":[{"type":"DRUG","name":"reslizumab","otherNames":["Cinquilâ„¢","CEP-38072","CTx55700"]}],"arms":[{"label":"Open-Label Reslizumab","type":"OTHER"}],"summary":"This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434).\n\nThe goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, or Discontinuation Due to AEs","timeFrame":"From start of study drug until end of treatment (mean [standard deviation {SD}] duration of treatment was 30.0 [5.89] months)","effectByArm":[{"arm":"Open-Label Reslizumab","deltaMin":177,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":36,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":190},"commonTop":["Pharyngolaryngeal pain","Headache","Upper respiratory tract infection","Nasopharyngitis","Influenza"]}}